Lowest-Rated StocksLowest-Rated Most-Downgraded StocksMost-Downgraded

NASDAQ:PTCT

PTC Therapeutics (PTCT) Stock Forecast, Price & News

$23.92

-0.90 (-3.63%)

(As of 09/22/2023 ET)

Compare

Today's Range: $23.87
▼
$24.84
50-Day Range: $23.92
▼
$41.80
52-Week Range: $23.57
▼
$59.84

Volume: 1.51 million shs
Average Volume: 1.23 million shs
Market Capitalization: $1.80 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $39.57

PTC Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 65.4% Upside
$39.57 Price Target
Short Interest: Bearish
9.82% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.38
Upright™ Environmental Score
News Sentiment: -0.21
Based on 38 Articles This Week
Insider Trading: Selling Shares
$465,007 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($5.46) to ($4.36) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

585th out of 965 stocks

Pharmaceutical Preparations Industry

274th out of 455 stocks

4.0

Analyst's Opinion

Consensus Rating
PTC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 3 buy ratings, 7 hold ratings, and 3 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $39.57, PTC Therapeutics has a forecasted upside of 65.4% from its current price of $23.92.
Amount of Analyst Coverage
PTC Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
9.82% of the outstanding shares of PTC Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
PTC Therapeutics has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.
Change versus previous month
Short interest in PTC Therapeutics has recently increased by 2.64%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
PTC Therapeutics does not currently pay a dividend.
Dividend Growth
PTC Therapeutics does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
PTC Therapeutics has received a 67.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Lipid-lowering medication (C10)", "Glucocorticoids", "Clinical research services for infectious diseases", and "Neuromuscular disorders medication" products. See details.
Environmental Sustainability
The Environmental Impact score for PTC Therapeutics is -1.38.

1.5

News and Social Media Coverage

News Sentiment
PTC Therapeutics has a news sentiment score of -0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 38 news articles for PTC Therapeutics this week, compared to 5 articles on an average week.
Search Interest
3 people have searched for PTCT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $465,007.00 in company stock.
Percentage Held by Insiders
Only 5.30% of the stock of PTC Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for PTC Therapeutics are expected to grow in the coming year, from ($5.46) to ($4.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PTC Therapeutics is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PTC Therapeutics is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTCT Price History

30 days | 90 days | 365 days | Advanced Chart

PTCT Stock News Headlines

September 21, 2023 | americanbankingnews.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) to Post Q3 2023 Earnings of ($1.31) Per Share, Leerink Partnrs Forecasts

September 20, 2023 | finance.yahoo.com

PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?

September 23, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

September 20, 2023 | americanbankingnews.com

PTC Therapeutics (NASDAQ:PTCT) Price Target Lowered to $23.00 at Bank of America

September 20, 2023 | americanbankingnews.com

FY2027 EPS Estimates for PTC Therapeutics, Inc. Lowered by Analyst (NASDAQ:PTCT)